Cantor Fitzgerald Upgrades Zealand Pharma A/S (OTCMKTS:ZLDPF) to Strong-Buy

Cantor Fitzgerald upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) to a strong-buy rating in a report released on Tuesday,Zacks.com reports.

Separately, JPMorgan Chase & Co. began coverage on Zealand Pharma A/S in a report on Friday, November 8th. They set an “overweight” rating for the company.

Zealand Pharma A/S Trading Up 2.1 %

Zealand Pharma A/S stock opened at $102.98 on Tuesday. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03. Zealand Pharma A/S has a 12 month low of $65.26 and a 12 month high of $141.74. The company’s fifty day simple moving average is $102.26 and its 200-day simple moving average is $117.80. The stock has a market cap of $7.31 billion, a P/E ratio of -42.38 and a beta of 0.89.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.